Norges Bank’s Black Diamond Therapeutics BDTX Stock Holding History

Norges Bank’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-210,300	Closed	-$583K	–	2069
2022 Q1	$583K	Hold	210,300	–	–	﹤0.01%	2092
2021 Q4	$1.12M	Sell	210,300 -64,000	-23%	-$447K	﹤0.01%	2099
2021 Q3	$2.32M	Buy	274,300 +194,300	+243%	+$1.92M	﹤0.01%	2029
2021 Q2	$975K	Hold	80,000	–	–	﹤0.01%	2122
2021 Q1	$1.94M	Sell	80,000 -20,000	-20%	-$539K	﹤0.01%	1998
2020 Q4	$3.21M	Hold	100,000	–	–	﹤0.01%	1913
2020 Q3	$3.02M	Hold	100,000	–	–	﹤0.01%	1926
2020 Q2	$4.22M	Hold	100,000	–	–	﹤0.01%	1886
2020 Q1	$2.5M	Buy	+100,000	New	+$3.04M	﹤0.01%	1906

Other funds holding BDTX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Norges Bank's BDTX Position: Q2 2022 in Review

Norges Bank sold out of Black Diamond Therapeutics (BDTX) in Q2 2022, closing a stake of 210,300 shares — an estimated $583K sold.

Norges Bank first reported a position in BDTX in Q1 2020 and held it in 9 quarters. The position peaked at $4.22M in Q2 2020. 74 funds tracked by Wall St. Rank hold BDTX as of Q2 2022.

Norges Bank reported no remaining Black Diamond Therapeutics position as of Q2 2022 after selling out during the quarter.
Norges Bank sold 210,300 Black Diamond Therapeutics shares in Q2 2022, an estimated $583K.
Norges Bank first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 9 quarters.
Norges Bank's Black Diamond Therapeutics position peaked at $4.22M in Q2 2020.
74 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2022.

Based on Norges Bank's 13F filing for Q2 2022, filed 11 Aug 2022.